Tobacco Center Faculty Blog

March 4, 2020

Stanton A. Glantz, PhD

My blog posts on the federal T21 law generated a lot of questions to me about enforcement and how the federal law relates to state laws.

The FDA just posted a website that clearly addresses these issues.  The bottom line in the T21 is the law everywhere in the country now with no exceptions.  For people who want details, it is worth spending a few minutes looking at the FDA's commonly asked questions.

February 23, 2020

Stanton A. Glantz, PhD

The FDA is about to close the docket on the question of whether to allow Philip Morris to make reduced risk or reduced exposure claims for IQOS.  This comment updates our earlier comments with more recent information that further strengthens the case for denying both claims.

A PDF of the comment is here.  The tracking number is 1k4-9f6q-znav.

FDA should not authorize Philip Morris International to market IQOS with claims of reduced risk or reduced exposure  


February 18, 2020

Stanton A. Glantz, PhD

In June 2019, after peer review, the Journal of the American Heart Association published “Electronic Cigarette Use and Myocardial Infarction Among Adults in the US Population Assessment of Tobacco and Health” by Dharma Bhatta and me.  Based on a cross-sectional analysis of the Population Assessment of Tobacco and Health (PATH) dataset, we found an association between e-cigarette use and having had a myocardial infarction (heart attack) that was independent of the effect of any current or former cigarette smoking by respondents.

One potential problem with such cross-sectional studies of the health effects of e-cigarette use is that some of the heart attacks could have occurred before e-cigarettes were available.  We addressed this potential problem in the paper by conducting a subsidiary analysis limiting the data to people who had heart attacks after 2007, when e-cigarettes first became available.  This additional analysis is described in the published paper:

February 7, 2020

Stanton A. Glantz, PhD

Lauren Lempert and I just sent this letter to Mitch Zeller at FDA urging them to withdraw the PMTA awarded to 22nd Century very low nicotine cigarettes.  This letter raises issues beyond the issues with the MRTP public comments we recently submitted.

February 7, 2020

Mr. Mitchell Zeller

Director, Center for Tobacco Products

Food and Drug Administration
10903 New Hampshire Avenue
Silver Spring, MD 20993 


Dear Mr. Zeller,

FDA issued marketing orders for 22nd Century’s Moonlight and Moonlight Menthol reduced nicotine cigarettes on December 17, 2019 based on premarket tobacco product applications (PMTAs) that used the names “VLN King and VLN Menthol King.” On October 2, 2019, 22nd Century submitted an amendment to its PMTAs changing the names of the subject cigarettes from “VLN” to “Moonlight” after FDA had already conducted its scientific review using the “VLN” names. Therefore, none of the evidence before FDA when it considered the PMTAs used the Moonlight names that 22nd Century is now authorized to use when it brings these products to market.

February 7, 2020

Stanton A. Glantz, PhD

Today we submitted this public comment to FDA and its Tobacco Products Scientific Advisory Committee.  The tracking number is 1k4-9evp-yi5f. A PDF is available here.

22nd Century’s VLN cigarettes marketing with modified exposure claims has not been tested and will likely be appealing to youth and young adults


Lucy Popova, PhD*; Bonnie Halpern-Felsher, PhD; Benjamin Chaffee, DDS, MPH, PhD; Lauren K. Lempert, JD, MPH; Stanton A. Glantz, PhD